Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
Not yet recruiting
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Registration Number
- NCT05837689
- Lead Sponsor
- Xiaojun Xu
- Brief Summary
A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next generation sequencing (NGS). The efficacy of blinatumomab clearing MRD detected by NGS will be analyzed, in order to see the potential of using NGS to guide MRD eradication by blinatumomab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Patients diagnosed with B cell precursor acute lymphoblastic leukemia
- Patients who received blinatumomab for consolidation
- Patients who were detected MRD positive by NGS before initiation of blinatumomab treatment
Exclusion Criteria
- Patients without data of NGS detection after receiving blinatumomab treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MRD clearance rate (MRD<0.00001%) before blinatumomab initiation (baseline), Day 15 of blinatumomab treatment, Day 29 of blinatumomab treatment The change of MRD will be detected by NGS, with sensitivity of 0.00001% and 0.01%, respectively
- Secondary Outcome Measures
Name Time Method